Introducing a new AccessPlus program - Simplified loan program for MiniMed™ 780G. Discover More

Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

You are here

Home » MiniMed 670G

INSPIRING CONFIDENCE
WITH THE WORLD'S
FIRST SELF-ADJUSTING
INSULIN PUMP SYSTEM

INSPIRING CONFIDENCE
WITH THE WORLD'S
FIRST SELF-ADJUSTING
INSULIN PUMP SYSTEM

The MiniMed™ 670G system offers SmartGuard™ Auto Mode™, the only technology that mimics some of the functions of a healthy pancreas by providing two levels of insulin delivery for type one patients 7 years or older.

SmartGuard® AUTO MODE FEATURES:

  • Automatically adjusts your basal (background) insulin every five minutes based on your CGM readings.*,#
  • Helps keep your sugar levels in your target range for fewer lows and highs — day and night.*,#,1
MiniMed<sup>®</sup> 670G

The MiniMed™ 670g system.

 

Water Resistance Waterproof pump, protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours.
Sizing The pump dimensions in inches are approximately 2.1 width x 3.78 length x 0.96 depth. The weight of the pump is approximately 3 ounces.
Environmental Conditions The MiniMed™ 670G insulin pump system is designed to withstand most conditions encountered in your daily life. Pump storage temperature range is from -4 °F (-20 °C) to 122 °F (50 °C). Air pressure range is from 700 hPa to 1060 hPa (10.2 psi to 15.4 psi)
Pump Memory At any time the user can review 90 days of pump history
Compatible Infusion Sets Medtronic Diabetes provides a variety of infusion sets to fit your needs.
Guardian™ Link 3 Transmitter Used with your pump for Continuous Glucose Monitoring (CGM). A device that connects to a glucose sensor. The transmitter collects data measured by the sensor and wirelessly sends this data to monitoring devices.
Bolus™ Speed Options
  • Standard: 1.5 units/minute
  • Quick: 15 units/minute
Bolus™ Programming Increments
  • 0.025 units
  • 0.05 units
  • 0.1 units
Altitude Range
  • Pump operating range is from 10.2 psiA (70.33 kPa) to 15.4 psiA (106.18 kPa)
  • Storage range is from 7.2 psiA (49.64 kPa) to 15.4 psiA (106.18 kPa)
Backlight
  • Type LED (Light-emitting Diode)
  • Time out 15 seconds (default), 30 seconds, one minute, three minutes
  • Time out when battery is low 15 seconds (default), 30 seconds
Basal Delivery Rate Range 0 to 35 units per hour or the Max Basal Rate amount, whichever is lower.
Guardian™ Sensor 3 Used with your pump for CGM. The sensor is a small part of the continuous glucose monitoring system that you insert just below your skin to measure glucose levels in your interstitial fluid.
Carelink™ USB Used to upload system data to the diabetes management software using a USB port on your computer.
One-press Serter The serter is used as an aid for inserting the sensor. It is indicated for single-patient use and is not intended for multiple patient use.
Battery & Power The pump requires one new AA (1.5 V) battery. For best results, use a new AA lithium (FR6) battery. The pump also accepts an AA alkaline (LR6) or a fully charged AA NiMH (HR6) nickel-metal hydride rechargeable battery.
Reservoir Medtronic reservoir MMT-332A, 3.0 ml (300-unit)
CONTOUR®NEXT LINK 2.4 Glucose Meter The MiniMed™ 670G system comes with a compatible meter. It wirelessly connects to your pump, allowing you to send BG meter readings to your pump.

Nicky time in range

DO YOUR PATIENTS KNOW ABOUT TIME IN RANGE?

Time in Range: The percentage of time glucose levels are between 3.9 -10 mmol/L, per unit of time.

Why it matters: More time in range means fewer severe highs and lows — and may result in a better quality of life.15,16

Clinical references
1. dQ&A Patient Panel. [Q4 2016 Summary Report]. dQ&A 2017. 2. American Diabetes Association. Promoting health and reducing disparities in populations. Standards of medical care in diabetes 2017. Diabetes Care. 2017;40(suppl 1):S6–S10 3. American Diabetes Association. Glycemic targets. Standards of medical care in diabetes 2017. Diabetes Care. 2017;40(suppl 1):S48–S56. 4. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type 1 and type 2 diabetes. Diabetologia. 2002;45(7):937-948. 5. Ayano-Takahara S, Ikeda K, Fujimoto S, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type1 diabetes. Diabetes Care. 2015;38(1):e1-e2. 6. Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407-1408. 7. Data On File. Medtronic Diabetes. Northridge, CA. 8. Data On File. Medtronic Diabetes. Northridge, CA. Continued access phase HCP interview notes. 9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes management. N Engl J Med. 1993;329(14):977-986. 10. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009; 32(8):1378-1383. 11. Bergenstal R, Tamborlane W, Ahmann A, et al. Effectiveness of sensor-augmented insulin pump therapy in type 1 diabetes. N Engl J Med. 2010; 363(4): 311-320. 12. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections. JAMA. 2017;317(4):371-378. 13. Bailey T, Wallace JF, Greene, C et al. Accuracy and user performance evaluation of the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system. Clin Chim Acta. 2015; 448:139 -145. 14. Data On File. Medtronic Diabetes. Northridge, CA. Patient survey of pivotal patients. 15. Vanstone, M, Rewegan, A, Brundisini, F, et al. Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: A systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2015; 15(17): 1–29. 16. Ayano-Takahara, S, Ikeda, K, Fujimoto, S, Hamasaki, A, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2015 Jan; 38(1): e1-e 17.Customer Training Phase-Data on File. 2. Priority Access Phase-Data on File (n>13,000)
*ADA glycemic recommendation for non-pregnant adults. More or less stringent glycemic goals may be appropriate for individual patients. An A1C goal of 7.5% is recommended across all pediatric age-groups. **Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G System can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 4.4-10 mmol/"L in non-pregnant adults with diabetes. Based on clinical study data in pivotal trial. Individual results may vary. § Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. Do not calibrate your CGM device or calculate a bolus using a
blood glucose meter result taken from an alternative site testing (palm) or from a control solution test.
Indications
The MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons age seven and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM), and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
Warnings
Important Safety Information: MiniMed™ 670G System
The safety of using Auto Mode, Suspend before low, and Suspend on low in people who have no pump experience is not known. Auto Mode, Suspend before low, and Suspend on low should not be used if insulin pump settings have not been previously established. Insulin pump settings include basal rates, insulin to carb ratio, or insulin sensitivity factors. Always discuss with your healthcare professional before using Auto Mode, Suspend before low, or Suspend on low.
Do not make treatment decisions, such as determining your insulin dose for meals, using the MiniMed 670G system CGM values, as they are not intended to be used to make such treatment decisions. The MiniMed 670G system CGM does not replace a BG meter. Always use the values from your BG meter for treatment decisions. BG values may differ from SG values. Using the SG readings for treatment decisions could lead to high or low BG.
Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycaemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.
The MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons age seven and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM), and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
Contraindications
Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

You may be interested in

CARELINK™ THERAPY MANAGEMENT SOFTWARE

Gain essential insights to help inform treatment decisions.



View it here

i-Port Advance™

Offer your patients a life with fewer injections.



View it here

THE MINIMED® 670G Real World Data

Retrospective Analysis of Carelink™ database 3,141 subjects with Diabetes Mellitus...



View it here

ONLINE LEARNING MODULES

Register your interest to receive access to learning modules.



View it here